Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

23 October 2026 · By · Wire by Fusion42

Published

23 October 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at sciencedaily.com →

◆ Verified

Fusion42 · 23 October 2026 · Fusion42 review

Wave Neuroscience and Texas A&M have developed a personalized Magnetic e-Resonance Therapy (MeRT) for PTSD that uses AI to tailor transcranial magnetic stimulation based on individual brain activity. Early trials show a 52% symptom reduction and 68% remission, significantly improving outcomes over existing treatments.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You can now offer PTSD treatment customised by brain activity, a leap beyond one-size-fits-all drugs. If your product or service targets mental health care, this opens a clear path to reach millions seeking more effective options.

◆ Coverage

1 source · 23 Oct 2026

◆ Related on Wire

◆ Topics

Healthptsdpersonalized-medicinemental-healthtmsai-healthtech